This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arendrup, M. C. Articles by Tvede, M. Search for Related Content PubMed PubMed Citation Articles by Arendrup, M. C. Articles by Tvede, M.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, September 2005, p. 4434-4440, Vol. 43, No. 9
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.9.4434-4440.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Seminational Surveillance of Fungemia in Denmark: Notably High Rates of Fungemia and Numbers of Isolates with Reduced Azole Susceptibility

Unit of Mycology and Parasitology, Statens Serum Institut, Copenhagen,¹ Department of Clinical Microbiology, Skejby Hospital, Aarhus University Hospital, Aarhus,² Department of Clinical Microbiology, Odense University Hospital, Odense,³ Department of Clinical Microbiology, Herlev University Hospital, Herlev,⁴ Department of Clinical Microbiology, Hvidovre University Hospital, Hvidovre,⁵ Department of Clinical Microbiology, Aalborg Hospital, Aarhus University Hospital, Aalborg,⁶ Department of Clinical Microbiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark⁷

Received 2 March 2005/ Returned for modification 10 April 2005/ Accepted 30 May 2005

The aim of this study was to present the first set of comprehensive data on fungemia in Denmark including the distribution of species and range of susceptibility to major antifungal compounds based on a seminational surveillance study initiated in 2003. The catchment area of the participating hospitals had a population of 2.8 million, or 53% of the Danish population. A total of 303 episodes of fungemia were registered (annual rate, 11 of 100,000 people or 0.49 of 1,000 hospital discharges). Candida species accounted for 97.4% of the fungal pathogens. C. albicans was the predominant species (63%), but the proportion varied from 57% to 72% among participating departments of clinical microbiology. C. glabrata was the second most frequent species (20%; range, 8% to 32%). C. krusei was a rare isolate (3%) and occurred only at two of the participating hospitals. Retrospective data retrieved from the Danish laboratory systems documented a continuous increase of candidemia cases since the early 1990s. For the 272 susceptibility-tested isolates, MICs of amphotericin B and caspofungin were within the limits expected for the species or genus. However, decreased azole susceptibility, defined as a fluconazole MIC of >8 µg/ml and/or itraconazole MIC of >0.125 µg/ml, was detected for 11 Candida isolates that were neither C. glabrata nor C. krusei. Including intrinsically resistant fungi, we detected decreased susceptibility to fluconazole and/or itraconazole in 87 (32%) current Danish bloodstream fungal isolates. We showed a continuous increase of fungemia in Denmark and an annual rate in 2003 to 2004 higher than in most other countries. The proportion of bloodstream fungal isolates with reduced susceptibility to fluconazole and/or itraconazole was also notably high.

This article has been cited by other articles:

• Dannaoui, E., Lortholary, O., Raoux, D., Bougnoux, M. E., Galeazzi, G., Lawrence, C., Moissenet, D., Poilane, I., Hoinard, D., Dromer, F., and the YEASTS Group, (2008). Comparative In Vitro Activities of Caspofungin and Micafungin, Determined Using the Method of the European Committee on Antimicrobial Susceptibility Testing, against Yeast Isolates Obtained in France in 2005-2006. Antimicrob. Agents Chemother. 52: 778-781 [Abstract] [Full Text]  
• Odds, F. C., Hanson, M. F., Davidson, A. D., Jacobsen, M. D., Wright, P., Whyte, J. A., Gow, N. A. R., Jones, B. L. (2007). One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 56: 1066-1075 [Abstract] [Full Text]  
• Arendrup, M. C., Denning, D. W., Pfaller, M. A., Diekema, D. J., Rex, J. H. (2007). Does One Voriconazole Breakpoint Suit All Candida Species?. J. Clin. Microbiol. 45: 2093-2094 [Full Text]  
• Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Meis, J. F., Gould, I. M., Fu, W., Colombo, A. L., Rodriguez-Noriega, E., and the Global Antifungal Surveillance Group, (2007). Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing. J. Clin. Microbiol. 45: 1735-1745 [Abstract] [Full Text]  
• Pfaller, M. A., Diekema, D. J. (2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin. Microbiol. Rev. 20: 133-163 [Abstract] [Full Text]  
• Gumbo, T., Drusano, G. L., Liu, W., Ma, L., Deziel, M. R., Drusano, M. F., Louie, A. (2006). Anidulafungin Pharmacokinetics and Microbial Response in Neutropenic Mice with Disseminated Candidiasis. Antimicrob. Agents Chemother. 50: 3695-3700 [Abstract] [Full Text]  
• Sandven, P., Bevanger, L., Digranes, A., Haukland, H. H., Mannsaker, T., Gaustad, P., the Norwegian Yeast Study Group, (2006). Candidemia in norway (1991 to 2003): results from a nationwide study.. J. Clin. Microbiol. 44: 1977-1981 [Abstract] [Full Text]  
• Uko, S., Soghier, L. M., Vega, M., Marsh, J., Reinersman, G. T., Herring, L., Dave, V. A., Nafday, S., Brion, L. P. (2006). Targeted Short-Term Fluconazole Prophylaxis Among Very Low Birth Weight and Extremely Low Birth Weight Infants. Pediatrics 117: 1243-1252 [Abstract] [Full Text]